Targeted drug trial aims to control tough cancers by blocking a key growth signal
NCT ID NCT06360575
Summary
This study is testing whether the drug crizotinib can help control advanced cancers that have a specific genetic change called a MET exon 14 deletion. It is for patients with solid tumors, lymphoma, or multiple myeloma that have stopped responding to other treatments. Participants take crizotinib pills twice daily to see if blocking this specific growth signal can shrink tumors or slow their progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.